Belfast, Northern Ireland, United Kingdom, November 2025 — Re-Vana Therapeutics, a leading biotechnology company pioneering sustained-release drug delivery platforms for ophthalmic diseases, has announced the appointment of Hans Christinger as its new Chief Business Officer. With more than two decades of experience across global biopharma organizations, Hans brings deep expertise in business development, alliance management, and strategic partnerships in neuroscience and ophthalmology.
At Re-Vana, Hans will lead corporate strategy, business development, and partnerships to accelerate the company’s growth and collaborations in long-acting ophthalmic therapies. His appointment aligns with Re-Vana’s mission to redefine ocular drug delivery and improve outcomes for millions affected by retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and diabetic macular edema.
Prior to joining Re-Vana Therapeutics, Hans served as Chief Business Officer at Neurvati Neurosciences, where he played a pivotal role in advancing neuroscience therapeutics and forming partnerships to expand access to innovative treatments for nervous system disorders.
He is also the Founder and CEO of Modig Life Sciences, a patient-centered company focused on accelerating transformative treatments in neuroscience and rare diseases. Earlier in his career, Hans held senior leadership positions at Ovid Therapeutics, where he served as Vice President of Business Development & Alliance Management, leading global collaborations and strategic alliances in the biotech sector.
Hans also brings significant ophthalmology experience from his tenure as Vice President of Business Development at Ophthotech, where he contributed to major licensing and partnership initiatives in retinal disease therapeutics. His prior roles include leadership positions at Abbott, Roche, and Vertex Pharmaceuticals, where he drove innovation through licensing and strategic collaborations across multiple therapeutic areas.
Hans began his scientific career as a Research Associate at Genentech, contributing to early discovery and translational research. He holds an MBA from Babson College’s F.W. Olin Graduate School of Business and an MS in Chemistry and Biochemistry from San Francisco State University.
About Re-Vana Therapeutics
Re-Vana Therapeutics is a biotechnology company developing sustained-release drug delivery platforms for the treatment of retinal and ophthalmic diseases. The company’s proprietary photo-crosslinked biodegradable hydrogel technologies — EyeLief®, EyeLief-SD™, and OcuLief® — enable controlled drug release over 6–12 months, significantly reducing the need for frequent intravitreal injections.
Re-Vana’s innovative approach is therapeutic-modality agnostic, successfully applied to over 20 different molecules across biologics, peptides, and small molecules. In July 2025, the company announced a strategic collaboration with Boehringer Ingelheim to co-develop long-acting ophthalmic therapies, further advancing its mission to enhance patient quality of life through reduced treatment burden and improved clinical outcomes.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
